Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term 10-year follow-up of fingolimod Phase II relapsing multiple sclerosis cohort
2013-002660-17Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Change in EDSS score from D2201 baseline at 10-year follow-up. Started Feb 2014; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-002660-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002660-17.